Prognostic value of 18F-FDG PET/CT Imaging in Recurrent Salivary Gland Cancers

Conclusions: TLG on restaging FDG-PET predicted PFS and OS in patients with RSGC; patients with predicted poor outcome may benefit from alternate, escalated treatment strategies. Multivariate analysis of clinicopathological and imaging parametersParameterPFS HR (95.0% CI)PFS p-valueOS HR (95.0% CI)OS p-valueHistologic subtype, Adenocarcinoma vs. Non-adenocarcinoma2.27 (1.33- 3.89)0.0031.60 (0.91-2.80)0.09TMTV1.01 (0.99-1.012)0.081.00 (1.00-1.011)0.14TLG1.00 (1.00-1.001)< 0.0011.00 (1.00-1.001)< 0.001

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Nakajima, R., Patel, S. G., Schoder, H. Tags: Head and Neck Posters Source Type: research